SOPHiA GENETICS S.A.(SOPH)Earnings, Financials & Key Ratios
SOPH•NASDAQ
$5.75
Price updated Jun 27, 2026
AboutSOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.Show more
- Revenue$77M+18.6%
- EBITDA-$61M-5.9%
- Net Income-$79M-26.4%
- EPS (Diluted)-1.17-23.2%
- Gross Margin61.88%-8.2%
- EBITDA Margin-79.46%+10.7%
- Operating Margin-91.79%+10.1%
- Net Margin-102.24%-6.6%
- ROE-110%-118.2%
SOPH Price & Volume
SOPHiA GENETICS S.A. (SOPH) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Revenue Growth Faces Severe Liquidity Constraints
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Accelerating
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Insufficient liquidity for operations
"SOPHiA GENETICS demonstrates promising top-line momentum with 22.0% year-over-year revenue growth in 2026Q1, yet the firm remains trapped in a cycle of persistent operating losses and capital erosion. While the platform-agnostic diagnostic model continues to scale, the company's inability to achieve operating leverage—evidenced by a -79.7% operating margin—creates a precarious financial outlook. Investors should remain cautious as the firm's cash balance of $65.4M against a TTM operating loss of $70.9M suggests an urgent need for external financing to sustain operations."
Verdict Logic
the company's cash position of $65.4M is insufficient to cover its ongoing operating losses, creating a high risk of dilution or insolvency.
SOPH Growth Metrics
SOPHiA GENETICS S.A. (SOPH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years22.16%
3 Years17.56%
TTM20.85%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-22.31%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-18%
Return on Capital
10 Years-51.99%
5 Years-42.4%
3 Years-47.3%
Last Year-58.75%
SOPH Recent Earnings
SOPHiA GENETICS S.A. (SOPH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.27-16.1%
$0.23
Rev
$22M+6.3%
$20M
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.28-17.9%
$0.24
Rev
$22M+5.9%
$20M
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.30-50.0%
$0.20
Rev
$19M-5.0%
$20M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.33+257.1%
$0.21
Rev
$18M-0.2%
$18M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.27vs $0.23-16.1% | $22Mvs $20M+6.3% |
| Q2 2026 | Mar 3, 2026 | $0.28vs $0.24-17.9% | $22Mvs $20M+5.9% |
| Q4 2025 | Nov 4, 2025 | $0.30vs $0.20-50.0% | $19Mvs $20M-5.0% |
| Q3 2025 | Aug 5, 2025 | $0.33vs $0.21+257.1% | $18Mvs $18M-0.2% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for SOPHiA GENETICS S.A. (SOPH)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.75 | $412.1M | -4.91 | 18.56% | -102.24% | -110% | — | |
| $261.91 | $37.51B | -172.31 | 35.9% | -9.05% | -15.13% | — | |
| $104.91 | $20.02B | -95.37 | 17.69% | -6.4% | -8.66% | — | |
| $60.49 | $4.83B | 73.77 | 16.01% | 16.25% | 6.86% | — | |
| $28.82 | $1.49B | -72.05 | 13.79% | -1.98% | -2.61% | — | |
| $176.55 | $26.82B | 32.39 | -0.78% | 19.43% | 32.84% | — |
Compare SOPH vs Peers
SOPHiA GENETICS S.A. (SOPH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when SOPH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SOPH Frequently Asked Questions
SOPHiA GENETICS S.A. (SOPH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is SOPHiA GENETICS S.A.'s revenue?
SOPHiA GENETICS S.A. (SOPH) reported $81.2M in revenue for fiscal year 2025. This represents a 220% increase from $25.4M in 2019.
How fast is SOPHiA GENETICS S.A. growing?
SOPHiA GENETICS S.A. (SOPH) grew revenue by 18.6% over the past year. This is strong growth.
Is SOPH profitable?
SOPHiA GENETICS S.A. (SOPH) reported a net loss of $80.9M for fiscal year 2025.
Dividend & Returns
What is SOPH's return on equity?
SOPHiA GENETICS S.A. (SOPH) has a return on equity (ROE) of -110.0%. Negative ROE indicates the company is unprofitable.
What is SOPHiA GENETICS S.A.'s free cash flow?
SOPHiA GENETICS S.A. (SOPH) had negative free cash flow of $45.4M in fiscal year 2025, likely due to heavy capital investments.